Addressing the energy crisis: using microbes to make biofuels

Much of the energy being used to power our lives comes from fossil fuels such as coal, natural gas and petroleum. These energy sources are non-renewable, are being exhausted and also pollute the air, water and soil with toxic chemicals. Their mining, transportation, refining and use are associated with a large carbon footprint that contributes significantly to global warming. In addition, the geopolitical complexities surrounding the main fossil fuel producers create risks and uncertainties around the world. Replacing fossil fuels with clean, renewable forms of energy is paramount to creating a sustainable and healthy future, and for laying the foundations for global political stability and prosperity. Using biomass from plants, microbes can produce biofuels that are identical to or perform as well as fossil fuels. In addition of creating sustainable energy, advancing the biofuel industry will create new, high-quality rural jobs whilst improving energy security.The given research was funded by Agencia Estatal de Investigación and Fondos FEDER (AEI/FEDER,EU) Ministerio de Ciencia e Innovacion (RTI2018- 094370-B-I00)

Hepatic effects of ketoconazole in the male Swiss Webster mouse: temporal changes in drug metabolic parameters

There have been conflicting observations regarding the effects of ketoconazole on hepatic metabolism. The objectives of these studies were to determine whether ketoconazole was an enzyme inducer or inhibitor in the mouse and then to establish the time frame of these ketoconazole-induced enzyme changes. Ketoconazole was administered (150 mg/kg p.o. × 4 days) to male Swiss Webster mice. Biochemical observations over a period of 6 days following treatment indicated that ketoconazole had a temporal biphasic effect on the liver. Although liver weight and microsomal protein were elevated, all other parameters monitored were lower at 2 h following ketoconazole treatment. At 24 h after the last dose of ketoconazole, hepatic biochemical parameters (liver wt., % liver wt./body wt., microsomal protein, and cytochrome P-450) were statistically elevated, while enzyme activities (benzphetamine N-demethylation, 6β- and 7α-hydroxylation of testosterone, formation of androstenedione and UDP-glucuronyltransferase) were inhibited. At 72 h the ketoconazole-induced changes in the hepatic biochemical parameters were comparable to those observed at 24 h, and enzymatic parameters generally appeared to be induced by ketoconazole, with the exception of benzphetamine N-demethylase and UDP-glucuronyltransferase, which exhibited lower enzyme activities. Ethoxyresorufin O-deethylase, 7α-hydroxylation of testosterone and glutathione S-transferase, on the other hand, were unaltered by ketoconazole treatment. The opposing effects of ketoconazole on benzphetamine N-demethylase and ethylmorphine N-demethylase at 72 h were further examined. Enzyme kinetics studies indicated that ketoconazole did not effect the Michaelis constants (Km) of the two substrates, but the maximum velocity (Vmax) of the reactions was altered. Six days after drug administration all monitored parameters had returned to control values, indicating the hepatic effects of ketoconazole in the male mouse were temporal.Key words: ketoconazole in mice, hepatic effects, biphasic effects, temporal effects, enzymic effect, enzyme inhibition, enzyme induction. </jats:p

SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation

KIT is a receptor tyrosine kinase (RTK) involved in several cellular processes such as regulation of proliferation, survival and differentiation of early hematopoietic cells, germ cells and melanocytes. Activation of KIT results in phosphorylation of tyrosine residues in the receptor, and recruitment of proteins that mediate downstream signaling and also modulate receptor signaling. Here we show that the SRC-like adaptor protein 2 (SLAP2) binds to wild-type KIT in a ligand-dependent manner and is furthermore found constitutively associated with the oncogenic mutant KIT-D816V. Peptide fishing analysis mapped pY568 and pY570 as potential SLAP2 association sites in KIT, which overlaps with the SRC binding sites in KIT. Expression of SLAP2 in cells expressing the transforming mutant KIT-D816V led to reduced cell viability and reduced colony formation. SLAP2 also partially blocked phosphorylation of several signal transduction molecules downstream of KIT such as AKT, ERK, p38 and STAT3. Finally, SLAP2 expression enhanced ubiquitination of KIT and its subsequent degradation. Taken together, our data demonstrate that SLAP2 negatively modulates KIT-D816V-mediated transformation by enhancing degradation of the receptor